Sanofi Pasteur Discusses C. Diff. Prevention on Developing a Preventative C. Diff. Infection Vaccine March 17, 2015 on C Diff Foundation's 'C Diff Spores & More'
Sanofi Pasteur, one of the leading vaccine manufacturers in the world, is currently conducting a Phase III clinical trial called Cdiffense in more than 20 countries across 5 continents to evaluate the safety, immunogenicity and efficacy of an investigational vaccine for the prevention of primary, symptomatic Clostridium difficile infection (CDI). The Cdiffense Phase III clinical program hopes to recruit up to 15,000 adults over 200 sites across the 20+ countries.
View full press release